San Francisco, Calif-based company Cytokinetics Inc recently announced that it will present two posters at the 22nd International Symposium on ALS/MND. The posters will outline data derived from a Phase II clinical trial encompassing a new drug treatment for amyotrophic lateral sclerosis (ALS) patients. The symposium will take place November 30, 2011 through December 2, 2011.
The International Symposium on ALS/MND hosts international researchers, health and social care professional who present and debate innovations in their respective fields.
According to Cytokinetics Inc, the first poster illustrates its data from a Phase II clinical trial that evaluated multiple fixed doses of CK-2017357, a skeletal muscle activator, in ALS patients who were not being treated with riluzole. The company’s second poster will provide attendees with a historic review of the ALS Functional Rating Scale – Revised (ALSFRS-R).
CK-2017357 emerged from Cytokinetics Inc’s skeletal muscle contractility program.
The company explains that CK-2017357 selectively activates the fast skeleton muscle troponin complex by heightening its calcium sensitivity. This increases skeletal muscle force and delays the onset, reducing the degree of muscle fatigue.
Cytokinetics Inc is a clinical-stage biopharmaceutical company, focusing on small molecule therapeutics that modulates muscle function for the potential treatment of serious disease and other medical conditions.
Source: Cytokinetics Inc